Recursion Pharmaceuticals Q1 EPS $(0.50) Beats $(0.52) Estimate, Sales $14.74M Miss $18.12M Estimate

Benzinga05-05

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.52) by 3.85 percent. This is a 28.21 percent decrease over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $14.74 million which missed the analyst consensus estimate of $18.12 million by 18.61 percent. This is a 9.30 percent increase over sales of $13.49 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法
1